Clinical Trial Update: Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating PolyIC in combination with a PD-1 monoclonal antibody for unresectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• PD-1 mAb (PD-1 monoclonal antibody)
• PolyIC

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: UNKNOWN